Drug profile · INN
atropine
ATROPINE SULFATE FGK
atropine (ATROPINE SULFATE FGK) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: intramuscular. Current US regulatory status: approved.
Drug details — atropine
- US status
- approved
- Class
- Sensory organs (S01)
- Route
- INTRAMUSCULAR
- Patents
- 1
- Programs
- 5
- Data quality
- 0.84
Quick answer
atropine (ATROPINE SULFATE FGK) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: intramuscular. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M1 antagonist
Primary target: Muscarinic acetylcholine receptor M1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | refused | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is atropine?
atropine (ATROPINE SULFATE FGK) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: intramuscular. Current US regulatory status: approved.
What is the brand name for atropine?
ATROPINE SULFATE FGK is a marketed brand name for atropine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of atropine?
atropine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.